ElectroCore outlines 30% to 40% 2027 revenue growth while targeting positive adjusted EBITDA by end of 2027 (NASDAQ:ECOR)
· seekingalpha.com
electroCore Q3 2026: record sales, narrowed losses, revised revenue outlook, and FDA Quell CIPN filing.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...